How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,633 results for

Uterine Fibroid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2621. Treatment with the gonadotrophin releasing hormone-agonist goserelin before hysterectomy for uterine fibroids. (PubMed)

Treatment with the gonadotrophin releasing hormone-agonist goserelin before hysterectomy for uterine fibroids. To investigate the effect of the gonadotrophin releasing hormone (GnRH)-agonist goserelin, given by monthly subcutaneous injection for three months prior to total abdominal hysterectomy for uterine leiomyomata, on the pre-operative symptoms, difficulty of operation and operative blood loss.Randomised placebo-controlled study.Patients were recruited from the gynaecological outpatient (...) departments from hospitals in Edinburgh, Glasgow and Newcastle.Seventy-one premenopausal women with uterine leiomyomata who were on the waiting list for hysterectomy.After the presence of leiomyomata was confirmed using ultrasonography, the women were randomised to receive either the GnRH-agonist goserelin by monthly subcutaneous injection or a sham injection for three months prior to operation. At the monthly visits, patients were asked about treatment related symptoms, fibroid related symptoms

1994 British journal of obstetrics and gynaecology Controlled trial quality: uncertain

2622. Role of goserelin-depot in the clinical management of uterine fibroids. (PubMed)

Role of goserelin-depot in the clinical management of uterine fibroids. On 30 women suffering from uterine fibroids, the monthly subcutaneous administration of goserelin depot (3.6 mg) for 6 (n = 22) or 12 months (n = 8) induced an about 50% shrinkage of uterus and fibroid volume, and within 3 months, an increase in the haematocrit value, with no metabolic side effects or detectable bone demineralization, evaluated by single photon absortiometry at distal radius. Both uterine and fibroid (...) volumes reversed to pretreatment values after 3 months of goserelin depot withdrawal. In comparison with untreated subjects, on another 10 patients a three month administration of goserelin depot reduced the loss of blood during the surgical removal of the uterus or fibroids. Present data indicate that goserelin depot is effective and relatively safe in the medical management of uterine fibroids. Although, goserelin depot cannot yet be proposed as a definite medical therapy, it may represent a useful

1994 Clinical and experimental obstetrics & gynecology Controlled trial quality: uncertain

2623. The effects of hormone replacement therapy on uterine fibroids in postmenopausal women. (PubMed)

The effects of hormone replacement therapy on uterine fibroids in postmenopausal women. To evaluate and compare the effects of two different modalities of hormone replacement therapy (HRT) on the size of uterine fibroids.Randomized clinical study.The Menopause Center of a public hospital.Postmenopausal women with small asymptomatic uterine fibroids were selected.One group was treated with 50 micrograms transdermal E2 plus 5 mg medroxyprogesterone acetate (MPA) continuously, whereas the second (...) group was given 0.625 mg conjugated equine estrogen plus 2.5 mg MPA continuously.The size of the uterine fibroids was measured before and after the first year of HRT.At the end of the first year on HRT, the size of the uterine fibroids was re-evaluated sonographically and no significant difference was found with the oral group, whereas there was a significant increase in the transdermal group.Hormone replacement therapy with 50 micrograms transdermal E2 plus 5 mg MPA increases the size

1996 Fertility and sterility Controlled trial quality: uncertain

2624. The place of Zoladex in deferred surgery for uterine fibroids. Zoladex Myoma Study Group. (PubMed)

The place of Zoladex in deferred surgery for uterine fibroids. Zoladex Myoma Study Group. Two hundred and forty-seven patients with uterine fibroids were randomized to surgery alone or 3 months' Zoladex (Zeneca, Macclesfield, Ches., UK) followed by surgery. Zoladex significantly reduced uterine and fibroid volumes (p = 0.0001). There was a significantly (p = 0.002) greater mean rise in haemoglobin from entry to preoperation in the Zoladex group (1 g/dl) compared with the surgery-alone group

1996 Hormone research Controlled trial quality: uncertain

2625. Diagnostic efficacy of compressed digitized real-time sonography of uterine fibroids. (PubMed)

Diagnostic efficacy of compressed digitized real-time sonography of uterine fibroids. The authors investigated the diagnostic efficacy of compression of real-time ultrasound (US) examinations.Low- and high-compression recordings (9:1 and 15:1, respectively) of examinations were generated by using Joint Photographic Experts Group algorithms. Seven radiologists used a five-level response scale to answer questions about the presence, number, and location of focal fibroid tumors in 67 randomly (...) that the sample size was adequate.Compressed images with compression ratios of 9:1 and 15:1 were diagnostically equivalent to uncompressed images of uterine fibroid tumors.

1997 Academic radiology Controlled trial quality: uncertain

2626. Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix. (PubMed)

Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix. A depot preparation of the third-generation gonadotrophin-releasing hormone (GnRH) antagonist Cetrorelix (SB-75) was used for preoperative treatment in twenty premenopausal patients with symptomatic uterine fibroids who were to undergo surgery. In a prospective, open, randomized setting 60 mg of Cetrorelix pamoate salt was administered i.m. on cycle day 2. Patients were (...) randomized for a second dose of 30 or 60 mg of Cetrorelix depot, which was administered according to the degree of oestradiol suppression (<50 pg/ml) on treatment day 21 or 28. Surgery was done after 6 or 8 weeks of treatment, depending on second dosage administration. Weekly transvaginal sonography (TVS) and magnetic resonance imaging (MRI) before and after treatment was performed, for fibroid volume assessment. Sixteen patients showed satisfactory suppression of gonadotrophins and sex steroid secretion

1998 Human reproduction (Oxford, England) Controlled trial quality: uncertain

2627. [Medical treatment of uterine fibroids with the LHRH antagonist: Cetrorelix]. (PubMed)

[Medical treatment of uterine fibroids with the LHRH antagonist: Cetrorelix]. A depot preparation of the LHRH-antagonist Cetrorelix was used for the preoperative treatment of 20 premenopausal women with symptomatic uterine fibroids to undergo surgery. In an open, prospective and randomised study, 60 mg of this depot preparation were administered i.m. at the second day of cycle. Patients were randomised for a second dosage of 60 mg or 30 mg to be injected on day 21 or day 28 of treatment (...) according to the degree of estradiols' suppression (< 50 pg/mL). The operation was carried out after six or eight weeks of treatment according to the timing of second dosages administration. Weekly transvaginal sonography as well as MRI before and after Cetrorelix treatment were performed for fibroids volume assessment; 16 patients showed satisfactory suppression of gonadotrophins and sexual steroids. No flare up effect was to be observed. In this group of patients the maximum reduction in fibroids size

1999 Contraception, fertilité, sexualité (1992) Controlled trial quality: uncertain

2628. The effect of submucous fibroids on the dose-dependent modulation of uterine bleeding by trimegestone in postmenopausal women treated with hormone replacement therapy. (PubMed)

The effect of submucous fibroids on the dose-dependent modulation of uterine bleeding by trimegestone in postmenopausal women treated with hormone replacement therapy. To assess the value of identifying endometrial structural abnormalities at baseline hysteroscopy in predicting the pattern of bleeding in postmenopausal women treated with hormone replacement therapy.A randomised, double-blind, dose-ranging study.A teaching hospital in the UK.One hundred and seventy-six healthy postmenopausal (...) women.Women were randomised to receive one of four doses of oral trimegestone (0.05, 0.1, 0.25 and 0.5 mg per day), from day 15-28, and a daily dose of 2 mg oral micronised oestradiol for six treatment cycles. Women completed diaries in which the bleeding episodes were recorded. Hysteroscopy under local anaesthesia and endometrial biopsy were performed at baseline and on day 24 of the last treatment cycle.Women with submucous fibroids had more prolonged (P = 0.026) and heavier (P = 0.002) progestogen

2000 BJOG Controlled trial quality: uncertain

2629. Identifying the indications for laparoscopically assisted vaginal hysterectomy: a prospective, randomised comparison with abdominal hysterectomy in patients with symptomatic uterine fibroids. (PubMed)

Identifying the indications for laparoscopically assisted vaginal hysterectomy: a prospective, randomised comparison with abdominal hysterectomy in patients with symptomatic uterine fibroids. To compare laparoscopically assisted vaginal hysterectomy (LAVH) and total abdominal hysterectomy (TAH) in patients with uterine fibroids.A prospective randomised study.The San Paolo Hospital, Milan.Sixty-two patients, who were not suitable for a vaginal hysterectomy, requiring treatment for uterine (...) fibroids.Randomisation between LAVH and TAH. Comparison of outcomes on the whole series, patients with uteri < or = 500 g (Group 1) and patients with uteri > 500 g (Group 2).To establish operating time, blood loss, complications, febrile morbidity, analgesics administration and hospital stay for both treatment approaches.Median uterine weight was 400 g in both LAVH and TAH group. Median operating time was longer for LAVH (135 min compared with 120 min for TAH; P = 0.001), but patients undergoing LAVH had less

2000 BJOG Controlled trial quality: uncertain

2630. Randomized double-blind study evaluating the efficacy on uterine fibroids shrinkage and on intra-operative blood loss of different length of leuprolide acetate depot treatment before myomectomy. (PubMed)

Randomized double-blind study evaluating the efficacy on uterine fibroids shrinkage and on intra-operative blood loss of different length of leuprolide acetate depot treatment before myomectomy. To determine whether length of pre-operative treatment with gonadotrophin-releasing hormone agonists (GnRHa) may have different effects on uterine shrinkage and intra-operative blood loss, 36 patients with symptomatic uterine fibroids awaiting myomectomy were randomly divided into two groups.Twenty (...) injections. In the short-term treated group the basal uterine volume decreased from 745+/-320 cm3 to 456+/-177 cm3 (39%) after two LA injections. The uterine volume decrease was statistically significant (p<0.05) after two LA injections in both groups while the decrease observed between two and six LA injections was not significant (p>0.05). The intra-operative blood-loss was not significantly different between the two groups studied, 315+/-93 cm3 and 336+/-88 cm3.Two pre-operative GnRHa depot injections

2001 Acta Obstetricia et Gynecologica Scandinavica Controlled trial quality: uncertain

2631. Comparison Study in the Treatment of Uterine Fibroids Uterine Fibroid Embolization Using BeadBlockâ„¢ Embolic Agent

Comparison Study in the Treatment of Uterine Fibroids Uterine Fibroid Embolization Using BeadBlockâ„¢ Embolic Agent Comparison Study in the Treatment of Uterine Fibroids Uterine Fibroid Embolization Using BeadBlock™ Embolic Agent - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Comparison Study in the Treatment of Uterine Fibroids Uterine Fibroid Embolization Using BeadBlock™ Embolic Agent The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00361036 Recruitment Status : Completed First Posted : August 7

2006 Clinical Trials

2632. Laparoscopic Occlusion of Uterine Vessels Compared to Uterine Fibroid Embolization for Treatment of Uterine Fibroids

Laparoscopic Occlusion of Uterine Vessels Compared to Uterine Fibroid Embolization for Treatment of Uterine Fibroids Laparoscopic Occlusion of Uterine Vessels Compared to Uterine Fibroid Embolization for Treatment of Uterine Fibroids - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Laparoscopic Occlusion of Uterine Vessels Compared to Uterine Fibroid Embolization for Treatment of Uterine Fibroids The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00277680 Recruitment Status : Unknown Verified January 2006

2006 Clinical Trials

2633. Add-back therapy for long-term use in dysfunctional uterine bleeding and uterine fibroids. (PubMed)

Add-back therapy for long-term use in dysfunctional uterine bleeding and uterine fibroids. The gonadotrophin-releasing hormone (GnRH) agonists are an efficacious medical approach for the management of both dysfunctional uterine bleeding (DUB) and uterine fibroids. However, due to the long-term effects of GnRH agonists on bone mass, their use is restricted to short courses. Add-back hormone replacement therapy (HRT) is one strategy that could minimise the hypo-oestrogenic effects of GnRH (...) agonists, without nullifying their therapeutic effects. In one study of add-back therapy with cyclical oestradiol/norgestrol in combination with Zoladex (goserelin acetate) in women with subjective DUB, the duration of menstruation, the number of days of heavy bleeding and objective blood loss were all significantly (P < 0.001) reduced. There was also significant (P < 0.001) symptomatic improvement. Furthermore, in 51 patients with symptomatic uterine fibroids, combined oestrogen/progestogen given

1996 British journal of obstetrics and gynaecology Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>